Introduction
H.R. Hygiene Products IPO is a BSE SME IPO scheduled to open on 29 July 2026 and close on 31 July 2026. The IPO price band is ₹83 to ₹88 per share, with a total issue size of around ₹53.95 crore.
The company manufactures sanitary napkins, baby care products and adult care products from Rajkot, Gujarat. The issue will list on the BSE SME platform, with Purva Sharegistry (India) Pvt. Ltd. as registrar and Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. as lead manager.
Public sources show different minimum application details, so investors should verify the final lot size, application amount and RHP details on the BSE SME page or broker platform before applying.
This guide explains the HR Hygiene Products IPO price, GMP, issue details, company business, financial trend, key risks and apply-or-avoid view so investors can make a more informed decision before applying.
HR Hygiene Products IPO Key Details
| Parameter | Details |
| IPO Open / Close | July 29 – July 31, 2026 |
| Allotment / Listing | August 3 / August 5, 2026 — BSE SME |
| Issue Type & Size | Book-built | ₹53.95 Cr = ₹43.17 Cr fresh (49.05 lakh shares) + ₹10.78 Cr OFS (12.25 lakh shares) | FV ₹10 |
| Price Band / Lot | ₹83–₹88 | 1,600 shares per lot | Retail minimum 2 lots (3,200 shares) = ₹2,81,600 |
| Quota Split | QIB 50% | NII 15% | Retail 35% |
| BRLM / Registrar | Marwadi Chandarana Intermediaries Brokers Pvt. Ltd. | Purva Sharegistry (India) Pvt. Ltd. |
| Registered Office | Survey No. 125/P2/P2, Plot 1–3, Village Lothada, Rajkot – 360002, Gujarat |
| Contact | +91 63545 54191 | compliance@hrhygiene.com | www.hrhygiene.com |
| DRHP Filed | September 28, 2025; schedule finalised after SEBI approval |
| Objects of Issue | New manufacturing facility at Rajkot + repayment of a portion of borrowings + general corporate purposes |
| GMP | ₹0 — no grey market activity recorded |
About H.R. Hygiene Products
H.R. Hygiene Products Limited is an FMCG company in the personal hygiene category. The company manufactures and sells products across women’s hygiene, baby care and adult care. InvestorGain describes the company’s product portfolio as including proprietary brands such as Femiss, Womanica, ElderFit and Bloom Baby.
The company started with sanitary napkins and later expanded into hygiene products for different consumer groups. It also undertakes contract manufacturing and private-label production, which means it may manufacture products for other brands or retailers in addition to selling its own brands.
This matters because the hygiene category has long-term demand drivers. Menstrual hygiene awareness, baby care consumption, adult incontinence care and e-commerce distribution are all structural themes. But this is also a competitive sector where large brands, regional players and private-label products compete on pricing, distribution and brand trust.
Financial Performance
| Metric | FY2024 | FY2025 | FY2026 |
| Revenue | ₹85.33 Cr | ₹115.15 Cr | ₹131.90 Cr |
| Profit After Tax | ₹4.66 Cr | ₹9.08 Cr | ₹11.41 Cr |
| PAT Margin | 6.08% | 7.90% | 8.73% |
| Total Borrowings / Debt | ₹24.76 Cr | ₹21.26 Cr | ₹21.53 Cr |
| Assets | ₹48.87 Cr | ₹90.56 Cr | ₹170.92 Cr |
| Debt-to-Equity | 3.96x | 0.67x | 0.51x |
| ROE / RoNW | 80.35% | 28.58% | 26.92% |
| ROCE | 41.17% | 32.30% | 24.86% |
Note: IPO Watch reports FY2026 revenue as ₹131.90 crore, while IPO Platform reports revenue from operations as ₹130.72 crore on an annualised/restated basis. The difference is small but should be checked against the RHP before publishing final numbers
H.R. Hygiene Products has shown steady growth, with revenue rising from ₹85.33 crore in FY2024 to ₹131.90 crore in FY2026. PAT also improved from ₹4.66 crore to ₹11.41 crore, while PAT margin increased to 8.73%.
Debt has reduced compared with FY2024, and debt-to-equity improved to 0.51x in FY2026. However, investors should check working capital, receivables, margin sustainability and whether the new Rajkot facility can generate healthy returns after listing.
HR Hygiene Products IPO GMP
As of 28 July 2026, InvestorGain shows H.R. Hygiene Products IPO GMP at ₹2, implying an estimated listing price of ₹90, or about 2.27% above the issue price. Investors should not apply only because of GMP. A small GMP may indicate limited listing-gain enthusiasm. But low GMP does not automatically mean the business is poor. For SME IPOs, subscription quality, QIB participation, financials, valuation and post-listing liquidity matter more than grey-market noise.To understand how grey market premium works and why it should not be the only reason to apply, read Acumen’s guide on what is GMP in IPO.
Why the Hygiene Category Matters
H.R. Hygiene Products operates in a category linked to everyday consumption. Sanitary napkins, baby diapers and adult care products are not luxury items. They are health, hygiene and dignity-linked products.
The opportunity is attractive because India’s hygiene consumption is still evolving. Awareness, income growth, women’s health initiatives, online marketplaces and modern retail can support category growth over time. The company’s presence across women’s hygiene, baby care and adult care also gives it more than one demand pool.
However, this sector is not easy. Large brands have deeper marketing budgets, stronger distribution networks and higher consumer trust. Smaller companies need to win through pricing, regional reach, private-label manufacturing, institutional supply or niche positioning.
Strengths of HR Hygiene Products IPO
1. Structural Demand Category
The company operates in personal hygiene, which has long-term demand support from awareness, healthcare needs, baby care and adult care.
2. Expansion-Led IPO
The proposed Rajkot manufacturing facility gives the IPO a clear capacity-expansion purpose. This is better than an issue that is only an exit route for existing shareholders.
3. Existing Operating History
The company was incorporated in 2016, so it is not a newly formed business listing only on projections. GoodReturns also lists the company as founded in 2016.
4. Multi-Category Portfolio
Women’s hygiene, baby care and adult care give the company access to different demand segments. InvestorGain lists brands such as Femiss, Womanica, ElderFit and Bloom Baby.
5. Pan-India Distribution Indicators
The reported distribution network across states and union territories is a positive operating signal, though investors should verify sales concentration and channel profitability in the RHP.
Key Risks Investors Should Know
1. SME IPO Liquidity Risk
BSE SME stocks can have lower trading volume after listing. Even if the business is good, exiting at the desired price may not always be easy.
2. Competition Risk
The hygiene market has strong brands, regional players, and private-label competition. H.R. Hygiene Products may need to compete on pricing, distribution and product quality.
3. Execution Risk
A major part of the IPO story depends on the new Rajkot manufacturing facility. Any delay, cost overrun, or lower-than-expected utilisation can affect returns.
4. Working-Capital Risk
Hygiene products require raw material, packaging, inventory and distribution credit. Investors should check receivables, inventory days and borrowings in the RHP.
5. GMP Is Not a Guarantee
GMP is unofficial. A ₹2 GMP or any future GMP change does not guarantee listing gain. Grey-market sentiment can change before listing.
6. Lot-Size and Capital Risk
SME IPO applications require higher capital than many mainboard IPOs. Since sources differ on minimum application values, investors should verify lot-size rules before applying.
Conclusion
H.R. Hygiene Products IPO gives investors exposure to India’s growing personal hygiene market, including sanitary napkins, baby care and adult care products.
However, it is a BSE SME IPO, so investors should consider liquidity risk, competition, working-capital needs and execution risk from the Rajkot expansion.
Before applying, check the final RHP, lot size, GMP trend, subscription data and financials. This IPO may suit investors who understand SME IPO risks and can take a medium-to-long-term view.For more IPO updates, market education and investment insights, visit Acumen Capital Market.
FAQs
1. Is H.R. Hygiene Products IPO good for long-term investors?
H.R. Hygiene Products operates in a growing personal hygiene category, including sanitary napkins, baby care and adult care products. This gives the business long-term demand potential. However, investors should check the company’s financials, margins, debt, working-capital needs and expansion plans before considering it for the long term.
2. What are the main risks in H.R. Hygiene Products IPO?
The key risks are SME IPO liquidity, strong competition from larger hygiene brands, working-capital pressure, execution risk from the Rajkot expansion and possible margin pressure from raw material or pricing changes. Investors should also remember that SME stocks can be more volatile after listing.
3. Should I apply for H.R. Hygiene Products IPO only for listing gains?
Investors should not apply only for listing gains. GMP can change quickly and does not guarantee listing performance. It is better to check subscription demand, valuation, financial performance, issue objectives and business risks before applying.
4. Why is the Rajkot manufacturing expansion important?
The planned Rajkot manufacturing expansion is important because it may help the company increase capacity, improve scale and serve wider demand. However, expansion also brings execution risk. Delays, cost overruns or weak capacity utilisation can affect future performance.
5. Who should consider applying for this IPO?
This IPO may suit investors who understand SME IPO risks, can handle lower liquidity and are willing to take a medium-to-long-term view. It may not be suitable for conservative investors or those looking only for quick listing gains.
Disclaimer:
This blog is intended for informational and educational purposes only and should not be considered investment advice or a recommendation to buy or sell any securities. Investments in the securities market are subject to market risks. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions. Past performance is not indicative of future results.
